AcuamarkDx offers a blood‑based diagnostic platform that uses multiplex qPCR assays and machine‑learning models to generate quantitative cancer risk scores from a ≤5 µL whole‑blood sample. The cloud‑hosted analytics pipeline delivers real‑time reports and integrates via HIPAA‑compliant APIs with EHR systems, enabling primary‑care physicians and clinical laboratories to conduct low‑cost early‑stage cancer screening and longitudinal monitoring.
Funding
Funding not disclosed
Founders
Product
Problem
Current primary‑care practice lacks routine, low‑cost screening tools for early‑stage cancer, resulting in infrequent testing, delayed diagnosis, and limited ability to monitor disease recurrence in asymptomatic patients.
Solution
AcuamarkDx delivers a blood‑based diagnostic platform that combines proprietary quantitative PCR (qPCR) assays with machine‑learning algorithms to detect cancer‑associated molecular signatures. The assay is designed for high analytical sensitivity and specificity, enabling detection of early‑stage malignancies before clinical symptoms appear. Results are processed through a cloud‑hosted analytics pipeline that generates quantitative risk scores and trend reports, supporting serial monitoring in primary‑care settings. The workflow requires only standard phlebotomy and can be performed in typical clinical laboratories, reducing per‑test cost and facilitating large‑scale screening programs. By integrating with electronic health record (EHR) systems via secure APIs, clinicians receive actionable insights without disrupting existing practice workflows.
Target Audience
Primary customers are primary‑care physicians and clinical laboratories seeking to incorporate routine, low‑cost cancer screening and longitudinal monitoring into standard patient visits, as well as health‑system networks aiming to expand early‑detection programs.
Features
- Proprietary multiplex qPCR panel targeting a validated set of circulating tumor DNA and RNA markers
- Machine‑learning model trained on multi‑cohort datasets to produce calibrated cancer risk scores with >90% sensitivity for stage I–II disease
- Minimal sample volume (≤5 µL whole blood) compatible with routine venipuncture and existing lab automation
- Cloud‑based analytics engine that normalizes assay data, applies quality control, and delivers real‑time reports via a web dashboard
- Secure, HIPAA‑compliant data transmission and storage with role‑based access controls
- RESTful API for bidirectional integration with major EHR platforms (FHIR‑compatible)
- Scalable pricing structure that supports high‑throughput testing in community clinics and large health systems